Q-omics provides the consensus-scored CCDC26 profile across patient tissues and cancer cell-line models. CCDC26 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC26 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, CCDC26 RNA expression shows 11,144 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where CCDC26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC26 survival associations across molecular data types. CCDC26 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC26 RNA expression–survival associations across cancer types. High CCDC26 expression shows unfavorable associations in UVM, THCA and LUSC, but favorable associations in COAD, LGG and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC26 RNA expression.
This table summarizes CCDC26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC26 shows lower tumor expression in COAD, KICH, LIHC and BLCA and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher CCDC26 RNA expression in normal versus tumor tissue (log2 FC = −0.047, t-test p < 0.001).
This table shows molecular features associated with CCDC26 in patient tissues and cancer cell lines. In patient samples, CCDC26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
